系統特異的なゲノムアーキテクチャは,増強剤と非コーディング疾患変異体を標的遺伝子プロモーターとリンクする
Biola M Javierre1, Oliver S Burren2, Steven P Wilder3
1Nuclear Dynamics Programme, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.
Cell
|November 19, 2016
まとめ
この研究はヒトの血液細胞における遺伝子プロモーターの相互作用をマッピングし,細胞特有の規制ネットワークを明らかにした. これらの発見は 遺伝的変異を病気と結びつけ ゲノム制御の理解を深めています
科学分野:
- ゲノミクス
- 分子生物学
- エピジェネティクス
背景:
- 規制要素と遺伝子プロモーターの間の長距離相互作用は,転写調節に不可欠である.
- これらの重要な相互作用のほとんどは特徴づけられず,ゲノム制御の完全な理解を妨げています.
研究 の 目的:
- ヒトの造血細胞における遺伝子プロモーターと規制要素の長距離相互作用を特定し,特徴づけること.
- これらの相互作用の細胞型特異性と機能的意義を調査する.
- 病気の遺伝子発見のために プロモーターのインタラクトームを活用する
主な方法:
- プロモーターキャプチャの Hi-C テクノロジーを利用した.
- 17種類のヒト原生血球細胞の31,253のプロモーターの相互作用を分析した.
主要な成果:
- 細胞型特異の広範囲のプロモーター相互作用が確認された.
- 活性プロモーターと強化剤の相互作用の強化が示された.
- プロモーターインタラクトームが 造血系関係を反映することを示した.
- 相互作用する領域で 遺伝的変異の濃縮が発見され 機能的な役割が示唆されています
- 病原体と潜在的標的プロモーターを結びつけ,病原体候補の遺伝子と経路を特定した.
結論:
- 主要な細胞プロモーターのインタラクトームは,ゲノム制御メカニズムに関する重要な洞察を提供します.
- このリソースは遺伝子調節を理解し,病気に関連した遺伝子を特定するのに価値があります.
- この発見は,細胞の分化過程における核構造のダイナミックな性質を強調しています.
関連する概念動画
01:37Epigenetic Regulation
4.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
4.0K
01:46Epigenetic Regulation
34.1K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.1K
01:11Genome-wide Association Studies-GWAS
16.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.4K
01:29Pharmacogenomics: Identification of New Drug Targets
59
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
59
02:39lncRNA - Long Non-coding RNAs
10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
02:40The Eukaryotic Promoter Region
19.3K
The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences. The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
19.3K